NCT00064025View on ClinicalTrials.gov

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

September 30, 2010

Conditions
Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Endometrioid Adenocarcinoma, Variant With Squamous DifferentiationRecurrent Uterine Corpus CarcinomaStage I Uterine Corpus CancerStage II Uterine Corpus CancerStage III Uterine Corpus CancerStage IV Uterine Corpus Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Medroxyprogesterone

Given IM

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgical hysterectomy

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00064025 - Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus | Biotech Hunter | Biotech Hunter